the results were classified according to concentration levels
the results were classified according to concentration levels: the results were classified according to concentration levels
Study summary
The research plan aims to evaluate the consistency of the digital PCR-based hepatitis B virus nucleic acid quantification technique with the existing Roche qPCR-based detection method. Approximately 200 samples of residual serum from patients with chronic hepatitis B, covering high, medium, low, and those below the Roche lower limit concentration or undetectable, will be collected. The two methods will be used for parallel testing. The main objective is to evaluate the quantitative consistency of the two methods within the quantifiable range of Roche (≥ 20 IU/mL); the secondary objectives include evaluating the qualitative detection rate of samples with concentrations below 20 IU/mL or undetectable nucleic acid.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Patients who have been diagnosed with chronic hepatitis B (in accordance with the diagnostic criteria of the "Chronic Hepatitis B Prevention and Treatment Guidelines (2022 Edition)") and are currently receiving NAs antiviral treatment for ≥ 6 months or have not received treatment and are ≥ 18 years old;
2. Remaining samples (serum) that have undergone combas HBV DNA testing and have clear test results, with the sample collection time frozen for ≤ 6 months;
3. The remaining sample volume is sufficient (≥ 1.0 mL), sufficient for digital PCR testing and necessary duplicate testing;
4. Samples from the same patient at different time points can be included as independent samples, but the sampling interval time needs to be recorded.
Exclusion Criteria:
1. Combine other liver virus infections such as HCV, HDV or HIV;
2. Poor sample quality, such as severe hemolysis, lipemia or repeated freezing and thawing ≥ 3 times;
3. The samples were not properly frozen and stored (-80℃) after collection or the temperature records were missing;
4. The clinical information is severely lacking, making it impossible to confirm the diagnosis and treatment status;
5. The duplicate samples already included at the same time point (only the first included sample is retained).
Primary outcome measure(s)
quantitative consistency — "Baseline, single cross-sectional testing at sample collection, through study completion" Evaluate the quantitative consistency of the self-developed digital PCR (ddPCR) method with the Roche Cobas TaqMan HBV DNA test (cobas HBV) within the quantifiable range (≥ 20 IU/mL)
Trial sites (1)
Facility
City
Region
Status
Beijing Ditan Hospital, Capital Medical University
Beijing
Beijing Municipality
More Beijing Municipal Administration of Hospitals trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.